These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 31292202)
1. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202 [TBL] [Abstract][Full Text] [Related]
2. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282 [TBL] [Abstract][Full Text] [Related]
4. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K; Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149 [TBL] [Abstract][Full Text] [Related]
5. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733 [No Abstract] [Full Text] [Related]
6. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513 [TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of glioma identified by genome-wide methylation profiling. Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961 [TBL] [Abstract][Full Text] [Related]
9. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826 [TBL] [Abstract][Full Text] [Related]
10. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948 [TBL] [Abstract][Full Text] [Related]
11. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139 [TBL] [Abstract][Full Text] [Related]
12. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018 [TBL] [Abstract][Full Text] [Related]
13. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232 [TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087 [TBL] [Abstract][Full Text] [Related]
16. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215 [TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles of long- and short-term glioblastoma survivors. Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739 [TBL] [Abstract][Full Text] [Related]
18. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
19. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577 [TBL] [Abstract][Full Text] [Related]
20. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry. Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]